Abstract: A method is provided for manufacturing a printed circuit board assembly. A method includes applying a liquefied radiant-heat material on a heating component mounted on the printed circuit board; mounting a shield unit on the printed circuit board in contact with the liquefied radiant-heat material; and simultaneously curing the liquefied radiant-heat material and bonding the shield unit.

Abstract: A method is provided for manufacturing a printed circuit board assembly. A method includes applying a liquefied radiant-heat material on a heating component mounted on the printed circuit board; mounting a shield unit on the printed circuit board in contact with the liquefied radiant-heat material; and simultaneously curing the liquefied radiant-heat material and bonding the shield unit.

Abstract: A shield can device is provided. The shield can device includes a frame which is fixed to a printed circuit board (PCB) and surrounds at least one circuit device as an electromagnetic shielding target, a cover which is coupled to the frame and closes an opening formed in a top of the frame, and a plurality of contact projections which are formed between the frame and the cover and allow the frame and the cover to be in electrical contact with each other.

Abstract: A shield is provided. The shield includes a shield frame surrounding an electronic component mounted on a printed circuit board and a shield cover partially coupled to the shield frame. The shield frame includes a column part mounted on the printed circuit board and a bending part bent from an upper end portion of the column part. An angle between both end portions of the bending part is smaller than about 90 degrees.

Abstract: A shield can device is provided. The shield can device includes a frame which is fixed to a printed circuit board (PCB) and surrounds at least one circuit device as an electromagnetic shielding target, a cover which is coupled to the frame and closes an opening formed in a top of the frame, and a plurality of contact projections which are formed between the frame and the cover and allow the frame and the cover to be in electrical contact with each other.

Abstract: An apparatus for operating a syringe has developed comprising: an upper semi-cylindrical tube section, semi-circular shaped locking groove and lower semi-cylindrical tube section. The upper semi-cylindrical tube section is integrally formed an upper head part with a threaded hole for axial movement. The lower semi-cylindrical tube section forms a top portion, intermediate portion and end portion. A diameter (Dc) at the intermediate portion larger than the diameter (Dtip) at end portion is gradually reduced from intermediate to end portion. The length of the tapered portion is same as that portion of the constant diameter. A tip portion has formed an opened semi-circular shape to simply overlap the syringe over the cartridge for easily snapping-in and out. The syringe piston moves downward with no reverse action when the piston press-unit is rotated, thus it is possible to inject the precise amount of medicine to a patient with constant pressure.

Abstract: A method is provided for manufacturing a printed circuit board assembly. A method includes applying a liquefied radiant-heat material on a heating component mounted on the printed circuit board; mounting a shield unit on the printed circuit board in contact with the liquefied radiant-heat material; and simultaneously curing the liquefied radiant-heat material and bonding the shield unit.

Abstract: A shield is provided. The shield includes a shield frame surrounding an electronic component mounted on a printed circuit board and a shield cover partially coupled to the shield frame. The shield frame includes a column part mounted on the printed circuit board and a bending part bent from an upper end portion of the column part. An angle between both end portions of the bending part is smaller than about 90 degrees.

Abstract: The present invention relates to a composition for cartilaginous tissue repair and to a production method therefor. The present invention comprises the steps of: (a) dissolving freeze-dried fibrinogen in an aprotinin solution; (b) dissolving freeze-dried thrombin in a stabilizing solution; (c) mixing an enriched collagen solution with thrombin and the stabilizing solution; and installing the fibrinogen solution (a) to one side of a dual kit and the solution (c) containing the collagen to the other side, and then mixing and injecting into damaged cartilaginous tissue. In the present invention, which is constituted as described above, biomaterials such as collagen and fibrin are mixed so as to allow damaged cartilaginous tissue to be repaired to a state allowing transplantation onto the tissue, and efficient regeneration is induced, thereby making it possible to reduce surgery-related stress on people and animals while inducing relatively rapid and efficient cartilage repair and regeneration.

Abstract: An apparatus for operating a syringe has developed comprising that: an upper semi-cylindrical tube section, semi-circular groove shaped locking slot and lower semi-cylindrical tube section. The upper semi-cylindrical tube section is integrally formed an upper head part with a threaded hole for axial movement. The lower semi-cylindrical tube section forms a top portion, intermediate portion and end portion. A diameter (Dc) at the intermediate portion is larger than the diameter (Dtip) at end portion, which is gradually reduced from intermediate to end portion. The length of tapered portion is same as that of the constant diameter portion. A tip portion has formed an opened semi-circular shape to simply overlap the syringe over the syringe mounting device for easily snapping-in and out. The syringe piston moves downward with no reverse action when the piston press unit is rotated, so that it is possible to inject the precise amount of medical to a patient with constant pressure.

Abstract: The present invention relates to a composition for cartilaginous tissue repair and to a production method therefor. The present invention comprises the steps of: (a) dissolving freeze-dried fibrinogen in an aprotinin solution; (b) dissolving freeze-dried thrombin in a stabilizing solution; (c) mixing an enriched collagen solution with thrombin and the stabilizing solution; and installing the fibrinogen solution (a) to one side of a dual kit and the solution (c) containing the collagen to the other side, and then mixing and injecting into damaged cartilaginous tissue. In the present invention, which is constituted as described above, biomaterials such as collagen and fibrin are mixed so as to allow damaged cartilaginous tissue to be repaired to a state allowing transplantation onto the tissue, and efficient regeneration is induced, thereby making it possible to reduce surgery-related stress on people and animals while inducing relatively rapid and efficient cartilage repair and regeneration.

Abstract: The present invention relates to a composition for cartilaginous tissue repair and to a production method therefor. The present invention comprises the steps of: (a) dissolving freeze-dried fibrinogen in an aprotinin solution; (b) dissolving freeze-dried thrombin in a stabilizing solution; (c) mixing an enriched collagen solution with thrombin and the stabilizing solution; and installing the fibrinogen solution (a) to one side of a dual kit and the solution (c) containing the collagen to the other side, and then mixing and injecting into damaged cartilaginous tissue. In the present invention, which is constituted as described above, biomaterials such as collagen and fibrin are mixed so as to allow damaged cartilaginous tissue to be repaired to a state allowing transplantation onto the tissue, and efficient regeneration is induced, thereby making it possible to reduce surgery-related stress on people and animals while inducing relatively rapid and efficient cartilage repair and regeneration.

Abstract: A method for separation the collagen from the various animal tissues is disclosed for preparing collagen solution and product using the same. The porcine tissues are processed to have proper form and size for acid-treatment. The acid-treatment is repeated with pepsin to separate type I or II collagens. The separated collagen is salt-treated for fractionation and ethanol-treated for obtaining 5˜10% of collagen from the initial tissue weight. The prepared tissues are processed for separating collagen through the collagen separating process. The separated collagen is processed for preparing product. The method for preparing product is comprised: treating a collagen solution having a predetermined concentration under a neutral condition at a low temperature, followed by overnight treatment at a temperature of 30 to 35° C.

Abstract: A compound for bone forming and a method for producing the same are provided using a mixture of an osteoblast and a bio-matrix. The method comprises: isolating osteoblasts from bone tissue and culturing the isolated osteoblasts to prepare an osteoblast suspension; and mixing the resulting osteoblast suspension with a bio-matrix to prepare an osteoblast therapeutic agent. A bone formation method is provided that results in no clinical graft rejection, and is capable of achieving effective and rapid bone formation via injection of a compound which has been pre-shaped to a certain extent, so as to alleviate problems associated with bone tissue formation in unwanted regions resulting from escape of injected osteoblasts from the targeted site for bone formation and then propagation thereof to other sites via the blood stream, which are caused by injection of an osteoblast suspension.

Abstract: An apparatus for operating a syringe piston is developed, which is comprised of: a syringe mounting section for fixedly holding a syringe, a thread hole formed at an upper head part of the syringe mounting section, and a piston press unit having a threaded rod, which is inserted into the thread hole so that the syringe piston press unit can move up and down along the thread hole, a locking slot for fixedly inserting and retaining the medicine filled syringe, a semi-cylindrical tube to assemble with the syringe mounting section. The syringe filled with medical cement is attached to the syringe mounting section and the syringe piston is moved downward with no reverse movement when the piston press unit is rotated, so the medical cement contained in the syringe is injected with a constant pressure, so that a predetermined amount of medical cement is precisely injected into a patient's body.

Abstract: The present invention relates to a method for separating bone marrow-derived nucleated cells for bone formation. The method comprises: the steps of: washing bone marrow; lysing red blood cells in the bone marrow; neutralizing the bone marrow lysate; purifying nucleated cells from the neutralized bone marrow; and mixing the nucleated cells with a maintenance buffer for bone formation. According to the invention, bone marrow-derived nucleated cells, which can be grafted into a site in need of bone formation or bone defect treatment, can be separated in a rapid and convenient manner. As a result, bone formation in emergency patients or patients, who require repeated surgical operations, can be effectively achieved by separating the nucleated cells for bone formation in surgical locations in a convenient and rapid manner and injecting the separated cells into the patients.

Abstract: A method is provided for utilizing a cell therapy product facility and an internet franchise market business comprising: producing a cell therapy product by a CT (Cell Therapy)-module (1) of prefabricated units having specific functions, and; storing of hematopoietic stem cells, bone marrow cells and other cells, by a BC (Banking of Cell and Tissue)-module (2) of prefabricated units having specific functions. Both modules eliminate contamination and maximize efficiency. It provides an operating method and a use method and business method for the above cell therapy product facility. The invention enables easy, low cost production of a product having sufficient quality to be transplanted into patients and put into clinical application within a short period of time. The facility module of the invention can be installed and used wherever adequate space is available. The invention provides improved quality and reliability of cell therapy products.

Abstract: A method for producing the fibrin contained semi-solid osteoblast composition has developed for treating the bone fracture. The method is comprised of: isolating osteoblasts from a bone tissue and culturing/proliferating the isolated osteoblasts in Dulbecco's Modified Eagle's Medium (DMEM) or Minimum Essential Medium, Alpha Modification (?-MEM) to prepare an osteoblast suspension. Then, mixing the resulting osteoblast suspension with a coagulation factor to prepare an osteoblast therapeutic agent. Accordingly, the fibrin contained semi-solid osteoblast composition of the present invention has capability to achieve the bone grafting for performing bone union without the clinical graft rejection. It is possible to uniformly distribute the fibrin mixed semi-solid osteoblast composition into the affected area of the bone fracture via injection. Therefore, the fibrin contained semi-solid osteoblast composition is effectively and rapidly cure the bone fracture via constant injection of into the affected area.

Abstract: A method for separation the collagen from the various animal tissues is disclosed for preparing collagen solution and product using the same. The porcine tissues are processed to have proper form and size for acid-treatment. The acid-treatment is repeated with pepsin to separate type I or II collagens. The separated collagen is salt-treated for fractionation and ethanol-treated for obtaining 5˜10% of collagen from the initial tissue weight. The prepared tissues are processed for separating collagen through the collagen separating process. The separated collagen is processed for preparing product. The method for preparing product is comprised: treating a collagen solution having a predetermined concentration under a neutral condition at a low temperature, followed by overnight treatment at a temperature of 30 to 35° C.

Abstract: 0A method for treating or preventing an elevated blood lipid level-related disease in a mammal, which comprises administering thereto an effective amount of rutin, quercetin or a mixture thereof.